AR029159A1 - Preparacion farmaceutica, envase que la contiene y uso en la preparacion de un medicamento util en la terapia de reemplazo hormonal - Google Patents
Preparacion farmaceutica, envase que la contiene y uso en la preparacion de un medicamento util en la terapia de reemplazo hormonalInfo
- Publication number
- AR029159A1 AR029159A1 ARP000101418A ARP000101418A AR029159A1 AR 029159 A1 AR029159 A1 AR 029159A1 AR P000101418 A ARP000101418 A AR P000101418A AR P000101418 A ARP000101418 A AR P000101418A AR 029159 A1 AR029159 A1 AR 029159A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- equivalent
- replacement therapy
- estrogenic activity
- package containing
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 2
- 230000003054 hormonal effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000009256 replacement therapy Methods 0.000 title 1
- 230000001076 estrogenic effect Effects 0.000 abstract 5
- 239000000126 substance Substances 0.000 abstract 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 2
- 230000000757 progestagenic effect Effects 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 238000002657 hormone replacement therapy Methods 0.000 abstract 1
- 229960000417 norgestimate Drugs 0.000 abstract 1
- KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una preparacion farmacéutica que comprende una pluralidad de dosis de administracion en fases alternadas de actividad estrogénica relativamente dominante, donde las fases de actividad estrogénica relativamente dominante comprenden una fase de actividad estrogénica relativamente dominante que comprende tres dosis diarias, o un equivalente de las mismas, de una sustancia que exhibe una actividad estrogénica equivalente a aproximadamente 1mg por día de 17b-estradiol, y una fase de actividad progestogénica relativamente dominante que comprende tres dosis diarias, o un equivalente de las mismas, de una combinacion de una sustancia que exhibe una actividad estrogénica equivalente a aproximadamente 17 mg por día de 17b-estradiol y una sustancia que exhibe una actividad progestogénica equivalente a aproximadamente 90 mg por día de norgestimato. Un envase que comprende dicha preparacion y el uso de esta ultima en la preparacion de un medicamento util en la terapia de reemplazo hormonal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12697099P | 1999-03-30 | 1999-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR029159A1 true AR029159A1 (es) | 2003-06-18 |
Family
ID=22427647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000101418A AR029159A1 (es) | 1999-03-30 | 2000-03-29 | Preparacion farmaceutica, envase que la contiene y uso en la preparacion de un medicamento util en la terapia de reemplazo hormonal |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US6747019B2 (es) |
| EP (1) | EP1165183A1 (es) |
| JP (1) | JP2002541126A (es) |
| KR (1) | KR20010112386A (es) |
| CN (1) | CN1200747C (es) |
| AR (1) | AR029159A1 (es) |
| AU (1) | AU3412300A (es) |
| CA (1) | CA2267743C (es) |
| CZ (1) | CZ20013493A3 (es) |
| HU (1) | HUP0200416A3 (es) |
| MX (1) | MXPA01009813A (es) |
| NZ (1) | NZ514463A (es) |
| PL (1) | PL202043B1 (es) |
| RU (1) | RU2245713C2 (es) |
| TR (1) | TR200102860T2 (es) |
| WO (1) | WO2000059577A1 (es) |
| ZA (1) | ZA200107976B (es) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2267743C (en) * | 1999-03-30 | 2011-07-26 | Robert F. Casper | Low dose estrogen interrupted hormone replacement therapy |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| JP2005519961A (ja) * | 2002-03-11 | 2005-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法 |
| AU2003213956A1 (en) * | 2002-04-03 | 2003-10-13 | Jencap Research Ltd. | Improved hormone replacement therapy |
| TW200404551A (en) * | 2002-05-17 | 2004-04-01 | Wyeth Corp | Hormone replacement therapy |
| RS20050184A (sr) * | 2002-08-28 | 2007-11-15 | Robert Casper | Režim zamene estrogena |
| DK1635843T3 (da) * | 2003-06-25 | 2009-05-04 | Bayer Schering Pharma Ag | Terapi, der omfatter dienogest for hormonerstatning og depression |
| EP1673071A1 (en) * | 2003-09-29 | 2006-06-28 | Novo Nordisk Femcare AG | Improved stability of progestogen formulations |
| PT1670440E (pt) * | 2003-09-29 | 2014-08-22 | Novo Nordisk Femcare Ag | Formulações hrt |
| RU2246249C1 (ru) * | 2004-05-05 | 2005-02-20 | Гальцова Наталья Евгеньевна | Способ профилактики сердечно-сосудистых заболеваний у женщин в климактерическом периоде на фоне заместительной гормональной терапии |
| CA2569738A1 (en) * | 2004-06-07 | 2005-12-22 | Duramed Pharmaceuticals, Inc. | Dispenser for progestin used for acute and maintenance treatment of dub |
| WO2006013464A1 (en) * | 2004-07-27 | 2006-02-09 | Amistad Pharma Sas | Hormone replacement therapy comprising a combination of 17-beta-oestradiol and chlormadinone acetate |
| US20060040904A1 (en) * | 2004-08-17 | 2006-02-23 | Ahmed Salah U | Vaginal cream compositions, kits thereof and methods of using thereof |
| US20060183724A1 (en) * | 2005-02-03 | 2006-08-17 | Diliberti Charles E | Compositions of unconjugated estrogens and methods for their use |
| US8217024B2 (en) * | 2005-12-27 | 2012-07-10 | Teva Women's Health, Inc. | Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof |
| US20080293683A1 (en) * | 2007-05-24 | 2008-11-27 | University Of Kansas Medical Center | Hormone Replacement Therapy |
| RU2428201C1 (ru) * | 2010-07-28 | 2011-09-10 | Государственное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого Министерства здравоохранения и социального развития Российской Федерации" | Способ лечения начального рака эндометрия |
| US20150031655A1 (en) * | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| CA2856520C (en) | 2011-11-23 | 2021-04-06 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| AU2017239645A1 (en) | 2016-04-01 | 2018-10-18 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| CN111035763A (zh) * | 2018-10-13 | 2020-04-21 | 合肥医工医药有限公司 | 一种治疗妇女更年期综合症的药物组合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1021196C (zh) * | 1986-12-29 | 1993-06-16 | 新泽西州州立大学(鲁杰斯) | 透皮雌激素/孕激素药剂单元、系统及方法 |
| ES2054784T3 (es) | 1987-08-08 | 1994-08-16 | Akzo Nv | Un metodo para la fabricacion de un implante. |
| AU630334B2 (en) * | 1987-09-24 | 1992-10-29 | Jencap Research Ltd. | Hormone preparations for hormone replacement therapy and contraceptive method |
| US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
| US5422119A (en) * | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
| US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
| US5256421A (en) * | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
| US5468736A (en) * | 1993-02-25 | 1995-11-21 | The Medical College Of Hampton Road | Hormone replacement therapy |
| DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| US5922349A (en) * | 1995-09-28 | 1999-07-13 | Schering Aktiengesellschaft | Hormone replacement therapy method and hormone dispenser |
| DE19540253C2 (de) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene |
| US6056972A (en) * | 1997-02-26 | 2000-05-02 | Dimera, Llc | Method for reducing coronary artery reactivity |
| CA2267743C (en) * | 1999-03-30 | 2011-07-26 | Robert F. Casper | Low dose estrogen interrupted hormone replacement therapy |
-
1999
- 1999-04-01 CA CA2267743A patent/CA2267743C/en not_active Expired - Lifetime
-
2000
- 2000-03-22 PL PL350854A patent/PL202043B1/pl not_active IP Right Cessation
- 2000-03-22 EP EP00912296A patent/EP1165183A1/en not_active Withdrawn
- 2000-03-22 TR TR2001/02860T patent/TR200102860T2/xx unknown
- 2000-03-22 JP JP2000609135A patent/JP2002541126A/ja active Pending
- 2000-03-22 WO PCT/CA2000/000315 patent/WO2000059577A1/en not_active Ceased
- 2000-03-22 HU HU0200416A patent/HUP0200416A3/hu unknown
- 2000-03-22 CZ CZ20013493A patent/CZ20013493A3/cs unknown
- 2000-03-22 CN CNB008079145A patent/CN1200747C/zh not_active Expired - Fee Related
- 2000-03-22 NZ NZ514463A patent/NZ514463A/xx unknown
- 2000-03-22 RU RU2001129160/14A patent/RU2245713C2/ru active
- 2000-03-22 MX MXPA01009813A patent/MXPA01009813A/es not_active Application Discontinuation
- 2000-03-22 KR KR1020017012502A patent/KR20010112386A/ko not_active Ceased
- 2000-03-22 AU AU34123/00A patent/AU3412300A/en not_active Abandoned
- 2000-03-29 AR ARP000101418A patent/AR029159A1/es not_active Application Discontinuation
-
2001
- 2001-09-28 ZA ZA200107976A patent/ZA200107976B/xx unknown
-
2002
- 2002-04-30 US US10/134,455 patent/US6747019B2/en not_active Expired - Lifetime
-
2004
- 2004-03-22 US US10/806,613 patent/US7078394B2/en not_active Expired - Fee Related
-
2006
- 2006-05-24 US US11/439,171 patent/US7320970B2/en not_active Expired - Fee Related
-
2007
- 2007-11-27 US US11/945,986 patent/US20080182828A1/en not_active Abandoned
-
2009
- 2009-09-08 US US12/555,196 patent/US20100063019A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1358104A (zh) | 2002-07-10 |
| US7078394B2 (en) | 2006-07-18 |
| EP1165183A1 (en) | 2002-01-02 |
| WO2000059577A1 (en) | 2000-10-12 |
| KR20010112386A (ko) | 2001-12-20 |
| US20060211663A1 (en) | 2006-09-21 |
| PL350854A1 (en) | 2003-02-10 |
| US20100063019A1 (en) | 2010-03-11 |
| US20080182828A1 (en) | 2008-07-31 |
| CA2267743A1 (en) | 2000-09-30 |
| HUP0200416A3 (en) | 2004-03-29 |
| HUP0200416A2 (hu) | 2002-07-29 |
| TR200102860T2 (tr) | 2002-02-21 |
| US6747019B2 (en) | 2004-06-08 |
| CZ20013493A3 (cs) | 2002-06-12 |
| CA2267743C (en) | 2011-07-26 |
| PL202043B1 (pl) | 2009-05-29 |
| US20020165209A1 (en) | 2002-11-07 |
| MXPA01009813A (es) | 2003-05-02 |
| RU2245713C2 (ru) | 2005-02-10 |
| US20040180867A1 (en) | 2004-09-16 |
| CN1200747C (zh) | 2005-05-11 |
| US7320970B2 (en) | 2008-01-22 |
| AU3412300A (en) | 2000-10-23 |
| ZA200107976B (en) | 2004-11-24 |
| JP2002541126A (ja) | 2002-12-03 |
| NZ514463A (en) | 2004-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR029159A1 (es) | Preparacion farmaceutica, envase que la contiene y uso en la preparacion de un medicamento util en la terapia de reemplazo hormonal | |
| HRP20070188A2 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| NO953874L (no) | Farmasöytisk preparat inneholdende lipofile legemidler | |
| BR9814837A (pt) | Procedimento e dispositivo para a dosagem de um medicamento | |
| CA2240329A1 (en) | Improved delivery of multiple doses of medications | |
| ES2062392T3 (es) | Medicamentos que comprenden salmeterol y fluticasona. | |
| AR028504A2 (es) | Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial | |
| AR031563A1 (es) | Una composicion farmaceutica para emplear en el tratamiento de trastornos menopausicos o posmenopausicos de estrogenos y acetato de medroxiprogesterona, una unidad de dosificacion farmaceutica y uso de una combinacion de estrogenos conjugados y acetato de medroxiprogesterona para la manufactura de u | |
| ATE309798T1 (de) | Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate | |
| UY26372A1 (es) | "imidazo-3-il-aminas bicíclicas procedimiento para su preparación y medicamentos que las contienen " | |
| ES2098920T3 (es) | Formulaciones farmaceuticas para el tratamiento de la dependencia a la nicotina. | |
| IT1255460B (it) | Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive | |
| ES2168241T1 (es) | Preparacion farmaceutica que contiene tolperisona para administrar por via oral. | |
| NO327588B1 (no) | Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| AR011437A1 (es) | Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento. | |
| JP2001513566A5 (es) | ||
| US6630149B1 (en) | Blister containing a transdermal therapeutic system and a single dose form of administration | |
| BR0010968A (pt) | Preparação farmacêutica, embalagem farmacêutica, método de tratamento e uso de uma substância estrogenicamente ativa e substância progestogenicamente ativa na preparação de um medicamento | |
| CR6467A (es) | Terapia interrumpida de reemplazo de hormonas con baja dosis de estrogeno | |
| IL126176A0 (en) | A pharmaceutical agent containing oestrogen and progesterone for sequential hormone therapy and a packaging unit containing the same | |
| AR109456A2 (es) | Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación | |
| AR029327A1 (es) | Uso de la levobupivacaina para la preparacion de medicamentos de aplicacion en el anestesiamiento de pacientes sujetos a intervencion de cirugia mayor | |
| JP2002520269A5 (es) | ||
| BR0008065A (pt) | Derivados de colestano insaturados e seu uso para a preparação de medicamentos que regulam meiose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |